Nocdurna (Desmopressin)

Desmopressin, the active ingredient in Nocdurna, is a vasopressin analog presented as a sublingual tablet for sublingual use. It is used to manage central diabetes insipidus, nocturnal enuresis, and certain bleeding disorders in appropriate patients.

GNH USA supplies Nocdurna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑compliant shipments to global healthcare providers.

Desmopressin is employed in conditions that involve impaired water balance or coagulation deficits.

- Central diabetes insipidus: reduces excessive urine output by increasing renal water reabsorption. - Nocturnal enuresis: decreases nighttime bedwetting episodes through antidiuretic action. - Bleeding disorders (e.g., hemophilia A, von Willebrand disease): raises plasma levels of clotting factor VIII and von Willebrand factor to improve hemostasis.

Desmopressin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, transient. - Abdominal cramps: mild discomfort. - Facial flushing: transient reddening of skin.

Serious or Rare Side Effects: - Severe hyponatremia: potentially life‑threatening low sodium levels. - Seizures: secondary to profound hyponatremia. - Thrombotic events: rare clot formation, especially in predisposed patients. - Allergic reactions (anaphylaxis): rare but may be severe.

When prescribing or dispensing Nocdurna, consider the following safety measures.

- Monitor serum sodium: check electrolytes regularly, especially in at‑risk patients. - Limit fluid intake: advise patients to avoid excessive water consumption to reduce hyponatremia risk. - Assess renal function: adjust use in patients with impaired kidney function. - Avoid use in uncontrolled hypertension: monitor blood pressure during therapy. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Desmopressin can interact with several medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Concomitant antidiuretic agents (e.g., oxytocin): risk of severe hyponatremia. - Carbamazepine: may reduce desmopressin efficacy. - NSAIDs: may potentiate antidiuretic effect and increase hyponatremia risk.

Moderate Interactions (Monitor Closely): - Warfarin: may increase bleeding risk in haemophilia patients. - Diuretics: may alter fluid and electrolyte balance. - CYP‑modulating drugs: limited data, monitor clinical response.